DEP® radiotheranostic conjugates have the potential to minimise off-target toxicity, optimise pharmacokinetics and enhance efficacy when used alone or in combination with other therapeutic approaches.
The versatility of Starpharma’s DEP® platform means it can be used with a wide range of therapies and types of molecules (e.g., small molecule drugs, peptides, antibodies, radioisotopes). This flexibility has allowed Starpharma to develop a range of DEP® radiotheranostics as well as its other DEP® programs.
DEP® radiotheranostics preclinical results
Starpharma has developed multiple novel DEP® radiotheranostic candidates. DEP® radiotherapeutics incorporate radioisotopes on to the DEP® scaffold and patent applications have been filed for DEP® radiotherapeutic candidates.
Targeted DEP® theranostics offer multiple benefits
Contact us if you are interested in establishing a partnership with Starpharma.